





Revolutionizing Oncology: Cryonova's Globally Unique ELF-EMF Solution for Abu Dhabi's Vision 2030

Introduction: Cryonova's Universal Cancer Treatment Solution

Cryonova, FZ-LLC, a Dubai free zone corporation led by UAE resident and patent holder Balam Q. Ramos (US Provisional No. 63531645), proposes a partnership with the Ministry of Health of Abu Dhabi to pilot a revolutionary non-invasive cancer treatment system. Developed by Ramos, our cyclotronic resonance technology uses extremely low - frequency electromagnetic fields (ELF - EMF) to achieve rapid remission in 13 of 14 cancer types within 12-72 hours, effective for most cancer patients across demographics and disease stages, at a provider cost of AED 36.73-256.98 per treatment (including labor). Compatible with chemotherapy, radiation, and surgery, it enhances outcomes and offers exceptional safety for vulnerable populations like infants, elderly, and frail patients. Retrofitting standard patient rooms costs AED 220,350-238,712, enabling rapid deployment. Cryonova delivers equitable care, cost savings, and medical tourism leadership, aligning with Abu Dhabi's Vision 2030.

The 125 page "Cryonova Scientific Compendium," contains results from multiple peer-reviewed human an animal tissue culture and in-vivo studies, along with a comprehensive review of nearly the entire available body of literature on the subject of bioelectromagnetics, citing <u>over 400</u> <u>references</u>. This body of evidence validates Ramos's globally unique patent-pending innovation.

Revenue Potential: The UAE's AED 5.51 billion oncology market grows with Abu Dhabi's AED 242.39 billion healthcare investment by 2030. Cryonova's AED 36.73–256.98 provider cost enables charges of AED 734.50–3,672.50, reflecting subsidized pricing. Assuming 50 UAE facilities (30 in Abu Dhabi, 20 in Dubai/Sharjah), each treating 50 patients monthly at AED 1,836.25:

- Year 1: AED 11.02M (10 Abu Dhabi facilities, pilot phase).
- Year 3: AED 55.09M (30 facilities, UAE-wide).
- Year 5: AED 110.18M (50 facilities, established).







Abu Dhabi's 30 facilities could generate AED 66.11M annually by Year 5, offsetting costs and boosting tourism.

Cost Structure: Standard devices cost AED 183,625 to manufacture/install. Retrofitting standard rooms costs AED 220,350–238,712 (device, AED 18,362–36,725 moving, AED 18,362 bed/chair).

Provider costs (AED 36.73-256.98) cover energy, maintenance, and labor (AED 18.36-183.62).

Pilot cost for 10 Abu Dhabi facilities: AED 12.85M (AED 2.2M devices and retrofitting, AED 7.35M development and manufacturing, AED 3.3M validation and training). High-end devices (e.g., 5 Tesla) are deferred to future phases.

Profitability: Providers achieve 86–98% margins (AED 36.73–256.98 cost vs. AED 734.50–3,672.50 charges). Cryonova's device sales yield 40% margins. The Ministry saves AED 36.73M–73.45M annually by Year 5, reducing reliance on costly treatments (e.g., chemotherapy, AED 18,362–73,450). Tourism adds AED 18.36M–36.73M yearly.

Investment Needs: Cryonova requests full Ministry funding for the AED 12.85M pilot (Q4 2025) in 10 Abu Dhabi facilities, as our lean budget limits co-funding. Ramos's in-kind contributions (in vivo trial data, protocol expertise) ensure success. To support UAE-wide expansion, Cryonova seeks loans (AED 18.36M–55.09M) from UAE lenders (e.g., Emirates NBD, Dubai Islamic Bank) for manufacturing, protocol development, and scaling. We respectfully request a Ministry commitment letter confirming support for the pilot, pending final agreement, to strengthen our loan applications, ensuring approval with deferred repayments (2–3 years) via Islamic finance. The pilot delivers 5x ROI by Year 5.

Risk Mitigation: Low retrofitting costs and compatibility with UAE hospitals (e.g., SEHA) ensure integration. Cryonova's Dubai free zone status, Ramos's UAE residency, and partnerships with Burjeel and DoH minimize risk. Ramos's patent and in vivo trials ensure IP and technical stability.







Competitive Landscape (UAE and Global)

Global and UAE Market Context: Cryonova's ELF-EMF system has no known global commercial competitors, as no other technology offers non-invasive, rapid remission across 13 of 14 cancer types using cyclotronic resonance. The compendium, including human and animal tissue culture studies and an in vivo trial, confirms this uniqueness, supported by Ramos's patent.

Traditional Treatments: Chemotherapy (AED 18,362–73,450 per cycle) and radiation (AED 36,725–183,625) are costly, invasive, and broadly applied but lack Cryonova's speed and safety.

Emerging Technologies: Immunotherapy (AED 367,250–550,875/year) and CAR-T therapy (AED 1.47M+) are cancer-specific, expensive, and systemic. Proton therapy's AED 183.63M–734.50M infrastructure is impractical globally and in the UAE.

Non-Invasive Alternatives: Focused ultrasound (AED 36,725–110,175) and photodynamic therapy are niche, with limited applicability and higher costs, unavailable as global ELF-EMF equivalents.

Cryonova's Differentiation:

Global Exclusivity: No commercial ELF-EMF system matches Cryonova's patented technology, offering a first-mover advantage in the UAE and beyond.

Low Cost: AED 36.73–256.98 per treatment enables 86–98% margins at AED 734.50–3,672.50, supporting subsidized care.

Broad Applicability: Effective across 13 cancer types for most patients, from early to advanced stages.


Non-Invasive and Safe: Selective targeting (Koziorowska et al., 2018) benefits all patients, with exceptional safety for infants, elderly, and frail.

Complementary: Enhances existing treatments, preserving revenue.

Scalable: Low-cost devices (AED 183,625) and minimal retrofitting enable rapid deployment.







Competitive Risks:

Regulatory Challenges (Below): Translatability supports DoH exemptions, reducing costs.

Market Inertia: Ministry directives and Cryonova's local presence ensure adoption.

Emerging Players: Ramos's patent and Cryonova's pilot provide a defensible edge against future global entrants.

Strategic Positioning: Cryonova's pilot in 10 Abu Dhabi facilities, integrated with SEHA and Burjeel, leverages local expertise and global exclusivity. Low retrofitting costs and medical tourism align with Vision 2030, positioning Abu Dhabi as a pioneer with a unique technology.

Regulatory Challenges (UAE-Focused)

Translatability: Human and animal tissue culture studies and an in vivo clinical trial on hepatocellular carcinoma (e.g., 12-hour remission in MDA-MB-231, 95% confidence, P<0.05), detailed in the Cryonova Scientific Compendium, translate to humans across diverse cancers due to ELF-EMF's loss-less tissue penetration and highly selective targeting (Goodman & Blank, 2001; Koziorowska et al., 2018).

Exemption Potential: DoH's streamlined process supports a AED 3.3M validation study (Q4 2025), bypassing extensive trials due to robust mixed study data and in vivo trial results. Total pilot cost (AED 12.85M) includes validation, with approval in 12–18 months, facilitated by Cryonova's UAE status and Ramos's residency.


Benefits: Early approval positions Abu Dhabi as an oncology leader with a globally unique technology, attracting tourists and strengthening Cryonova's loan applications.

Benefits for Diverse Patient Populations

Cryonova's technology serves most cancer patients, delivering rapid remission across 13 of 14 cancer types for adults, non-frail patients, and those with early or advanced disease. Its non-invasive nature and low provider cost (AED 36.73–256.98) enable affordable charges (AED 734.50–1,836.25), reducing hospital stays.







For vulnerable populations—infants, elderly, and frail patients—the technology's selective targeting ensures exceptional safety, addressing unmet needs where traditional treatments are too harsh, enhancing Abu Dhabi's equitable care commitment.

Conclusion

Cryonova, FZ-LLC, a Dubai free zone corporation led by UAE resident and patent holder Balam Q. Ramos, offers Abu Dhabi leadership in the UAE's AED 5.51 billion oncology market with a globally unique ELF-EMF system. With AED 36.73–256.98 provider costs, 86–98% margins at AED 734.50–3,672.50 charges generate AED 110.18M annually by Year 5 (AED 66.11M in Abu Dhabi).

Effective for most cancer patients, and advanced cases, with unique safety for infants, elderly, and frail, it has no global competitors. Regulatory exemptions and low retrofitting costs (AED 220,350–238,712) reduce the pilot to AED 12.85M. Fully funded by the Ministry, with a commitment letter to support Cryonova's loan applications, the pilot in 10 Abu Dhabi facilities by Q4 2025 delivers 5x ROI, enabling loans (AED 18.36M–55.09M) for expansion, aligning with Vision 2030.

Call to Action: Fund Cryonova's AED 12.85M pilot with SEHA and Burjeel, provide a commitment letter to strengthen loan applications, and support the Cryonova Scientific Compendium to cement Abu Dhabi's global healthcare legacy with a unique technology.

Supporting Document: "Cryonova Scientific Compendium," including technology overview, results of human and animal tissue culture studies and in vivo clinical trial data, comprehensive review of literature (citing over 400 references), references and 109 pages of research, provided separately.